Biotech Business - June 1, 2022
Spago Nanomedical carries out a rights issue of up to 61.8 million SEK
The Board of Directors of Spago Nanomedical has resolved to carry out a rights issue with preferential rights for existing shareholders of up to 61.8 MSEK before issue costs. Four (4) shares in Spago Nanomedical entitle for subscription of five (5) new shares in the Rights Issue at a subscription price of SEK 1.20 per […]
Intellectual Property - May 2, 2022
Spago Nanomedical receives extended patent protection in USA
Spago Nanomedical has received notice from the United States Patent and Trademark Office (USPTO) that it intends to grant the company’s patent application including a critical component of the SpagoPix candidate drug SN132D. The patent will be granted following confirmation of Spago Nanomedical and payment of applicable fees, states the company. The granted patent is […]
Intellectual Property - April 20, 2022
Spago Nanomedical receives extended patent protection in Japan
Spago Nanomedical has received notice from the Japanese Patent Office (JPO) that it intends to grant the company’s patent application including a critical component of the SpagoPix candidate drug SN132D. JPO has issued a Notice of Allowance which means the patent will be granted following confirmation of Spago Nanomedical and payment of applicable fees. The […]
Clinical Trials - March 2, 2022
Spago Nanomedical receives go-ahead to include patients with pancreatic cancer
Spago Nanomedical has received approval from the Swedish Medical Products Agency to initiate recruitment of patients with pancreatic cancer for the clinical study with the contrast agent SN132D. ”By including another patient group, we can in a cost-effective way demonstrate a broader use of SN132D and build additional value in the SpagoPix project at an […]
Clinical Trials - January 25, 2022
Positive preclinical results from Spago Nanomedical
Spago Nanomedical has announced new results which show that the company’s candidate drug Tumorad significantly reduces tumor growth and prolongs survival in a preclinical model for colorectal cancer. Together with previously communicated clinical and preclinical results, the new results provide additional support for the company’s platform technology with nanoparticles for use in several different cancer […]
Clinical Trials - December 13, 2021
Spago’s Tumorad shows good safety in preclinical studies
Spago Nanomedical has completed the studies in the regulatory preclinical program with its leading candidate drug Tumorad (SN201). It displays a good safety margin to clinically relevant doses, states the company. “The completion of the regulatory preclinical studies is an important step towards the clinical development phase. The preparations for the first study with SN201 […]
